TR201916829A2 - Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari - Google Patents

Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari Download PDF

Info

Publication number
TR201916829A2
TR201916829A2 TR2019/16829A TR201916829A TR201916829A2 TR 201916829 A2 TR201916829 A2 TR 201916829A2 TR 2019/16829 A TR2019/16829 A TR 2019/16829A TR 201916829 A TR201916829 A TR 201916829A TR 201916829 A2 TR201916829 A2 TR 201916829A2
Authority
TR
Turkey
Prior art keywords
metformin
dapaglyflozin
dual
tablet formulations
formulations containing
Prior art date
Application number
TR2019/16829A
Other languages
English (en)
Inventor
Ulusoy Bozyel Müge
Dedeoğlu Yavuz
Taşkin Abdullah
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2019/16829A priority Critical patent/TR201916829A2/tr
Priority to PCT/TR2020/050996 priority patent/WO2021086292A1/en
Priority to EP20881133.1A priority patent/EP4051246B1/en
Publication of TR201916829A2 publication Critical patent/TR201916829A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Buluş, dapagliflozin veya dapagliflozinin farmasötik olarak kabul edilebilir bir tuzu ve metformin ve metforminin farmasötik olarak kabul edilebilir bir tuzu ile gerçekleştirilen çift katmanlı tablet formülasyonlar ile ilgilidir.
TR2019/16829A 2019-10-31 2019-10-31 Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari TR201916829A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2019/16829A TR201916829A2 (tr) 2019-10-31 2019-10-31 Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari
PCT/TR2020/050996 WO2021086292A1 (en) 2019-10-31 2020-10-27 Bilayer tablet formulations comprising dapagliflozin and metformin
EP20881133.1A EP4051246B1 (en) 2019-10-31 2020-10-27 Bilayer tablet formulations comprising dapagliflozin and metformin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2019/16829A TR201916829A2 (tr) 2019-10-31 2019-10-31 Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari

Publications (1)

Publication Number Publication Date
TR201916829A2 true TR201916829A2 (tr) 2021-05-21

Family

ID=75716198

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/16829A TR201916829A2 (tr) 2019-10-31 2019-10-31 Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari

Country Status (3)

Country Link
EP (1) EP4051246B1 (tr)
TR (1) TR201916829A2 (tr)
WO (1) WO2021086292A1 (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022119543A1 (en) * 2020-12-03 2022-06-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
TR202019590A2 (tr) * 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
TR202019592A2 (tr) * 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Amorf dapagliflozinin katı farmasötik formülasyonları
EP4212150A1 (en) * 2022-01-13 2023-07-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet composition comprising amorphous dapagliflozin and metformin
WO2026003869A1 (en) * 2024-06-26 2026-01-02 Manish Goswami Modified release oral tablets for management of diabetes and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
EP3315124B1 (en) * 2009-11-13 2021-01-06 Astrazeneca AB Bilayer tablet formulations
CA2802335A1 (en) * 2010-06-22 2011-12-29 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect

Also Published As

Publication number Publication date
EP4051246A4 (en) 2023-11-15
WO2021086292A1 (en) 2021-05-06
EP4051246B1 (en) 2026-03-18
EP4051246A1 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
TR201916829A2 (tr) Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
JOP20220008A1 (ar) مثبطات parp1
ECSP17084331A (es) Formulaciones farmacéuticas
CO2021017317A2 (es) Células seguras e invisibles para el sistema inmunitario
TN2017000495A1 (en) Notch pathway signaling inhibitor compounds.
CY1110097T1 (el) Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων
BR112017028140A2 (pt) formulações farmacêuticas
DOP2020000160A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
TR201914043A1 (tr) Dapagli̇flozi̇n ve metformi̇n i̇çeren efervesan tablet formülasyonlari
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
MX2022003585A (es) Metodos para tratar hiperfenilalaninemia.
EA202090270A1 (ru) Новые замещенные производные ксантина
MX2020011814A (es) Anticuerpo anti-tlr7 humano.
TR201721824A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren modi̇fi̇ye salim sağlayan kombi̇nasyon
TR201713954A2 (tr) Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari
TR201913472A2 (tr) Vi̇ldagli̇pti̇n ve metformi̇n i̇çeren bi̇r kombi̇nasyon
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
TR201914406A2 (tr) Sapropteri̇n di̇hi̇droklorür ve en az bi̇r farmasöti̇k eksi̇pi̇yan i̇çeren kati oral farmasöti̇k formülasyonlar
TR201818307A2 (tr) Di̇meti̇l fumarat i̇çeren bi̇r kompozi̇syon
TR201101809A1 (tr) Vildagliptin ve glimepirid kombinasyonları.
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας
MX2019001202A (es) Compuesto que inhibe la formacion de complejo de c-myc/max/adn.